Journal
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 57, Issue 2, Pages 205-214Publisher
WILEY
DOI: 10.1111/apt.17286
Keywords
-
Ask authors/readers for more resources
This study aimed to test the impact of shared decision making (SDM) on choice of therapy, decision quality, and provider trust in patients with Crohn's disease. The results showed that patients who received the SDM intervention more frequently chose combination therapy, had lower decisional conflict, and had greater trust in their provider.
Background Crohn's disease requires effective patient-clinician communication for successful illness and medication management. Shared decision making (SDM) has been suggested to improve communication around early intensive therapy. However, effective evidence-based SDM interventions for Crohn's disease are lacking, and the impact of SDM on Crohn's disease decision making and choice of therapy is unclear. Aim To test the impact of SDM on choice of therapy, quality of the decision and provider trust compared to standard Crohn's disease care. Methods We conducted a multi-site cluster randomised controlled trial (in 14 diverse gastroenterology practices in the US. Results A total of 158 adult patients with Crohn's disease within 15 years of their diagnosis, with no prior Crohn's disease complications, and who were candidates to receive immunomodulators or biologics, participated in the study. Among these, 99 received the intervention and 59 received standard care. Demographics were similar between groups, although there were more women assigned to standard care, and a slightly shorter disease duration among those in the intervention group. Participants in the intervention group more frequently chose combination therapy (25% versus 5% control, p < 0.001), had a significantly lower decisional conflict (p < 0.05) and had greater trust in their provider (p < 0.05). Conclusions With rapidly expanding medication choices for Crohn's disease and slow uptake of early intensive therapy, SDM can personalise treatment strategies and has the potential to move the field of Crohn's disease management forward with an ultimate goal of consistently treating this disease early and intensively in appropriate patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available